Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AFL6 | ISIN: US87164F1057 | Ticker-Symbol: 1T3
Stuttgart
06.06.25 | 08:02
9,750 Euro
0,00 % 0,000
1-Jahres-Chart
SYNDAX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SYNDAX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,10010,20017:21
10,10010,20017:09

Aktuelle News zur SYNDAX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SYNDAX PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)19NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June...
► Artikel lesen
DoSyndax Pharmaceuticals auf der Jefferies-Konferenz: Strategisches Wachstum und Expansion-
28.05.Syndax Pharmaceuticals auf dem 6. Jährlichen Onkologie-Innovationsgipfel: Strategische Einblicke2
16.05.Syndax Pharmaceuticals Inc - 8-K, Current Report2
14.05.Syndax Pharmaceuticals, Inc.: Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo (axatilimab-csfr)8
12.05.Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer176- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW...
► Artikel lesen
06.05.Scotiabank raises Syndax stock target to $17 on strong sales5
06.05.BofA raises Syndax stock price target to $26 on strong Q1 update3
06.05.Syndax pharmaceuticals outlines $750M opportunity for Revuforj in initial market2
05.05.Syndax Q1 2025 slides: Revuforj revenue hits $20M, cash position remains strong2
05.05.Syndax Pharmaceuticals, Inc.: Syndax Reports First Quarter 2025 Financial Results and Provides Business Update223- $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch - - $13.6 million in Niktimvo (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch...
► Artikel lesen
05.05.Syndax Pharmaceuticals Inc - 10-Q, Quarterly Report1
05.05.Syndax Pharmaceuticals Inc - 8-K, Current Report1
02.05.Syndax Pharmaceuticals Q1 2025 Earnings Preview6
02.05.Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)87NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1...
► Artikel lesen
04.04.Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)151NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced...
► Artikel lesen
21.03.Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth6
05.03.Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)133NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced...
► Artikel lesen
04.03.Syndax Pharmaceuticals Inc - S-8, Securities to be offered to employees in employee benefit plans-
04.03.H.C. Wainwright maintains Buy on Syndax stock, $51 target2
Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1